We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Miragen Therapeutics Inc | NASDAQ:MGEN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 23.01 | 23.01 | 23.95 | 0 | 01:00:00 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
47-1187261
|
(State or other jurisdiction of
Incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
|
|
|
|
|
Large accelerated filer
|
|
¨
|
|
Accelerated filer
|
|
x
|
Non-accelerated filer
|
|
¨
|
|
Smaller reporting company
|
|
x
|
|
|
|
|
Emerging growth company
|
|
¨
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Title of Securities
to be Registered |
|
Amount
to be Registered(1) |
|
Proposed
Maximum Offering Price per Share(2) |
|
Proposed
Maximum Aggregate Offering Price(2) |
|
Amount of
Registration Fee |
|||||
Common Stock, par value $0.01 per share
|
|
|
|
|
|
|
|
|
|
||||
– Shares reserved for future grant under the 2016 Equity Incentive Plan
|
|
1,394,475
|
|
(3
|
)
|
|
$0.71
|
|
$990,077.25
|
|
$128.52
|
||
– Shares reserved for future grant under the 2016 Employee Stock Purchase Plan
|
|
348,618
|
|
(4
|
)
|
|
$0.71
|
|
$247,518.78
|
|
$32.13
|
||
Total
|
|
1,743,093
|
|
|
|
N/A
|
|
$1,237,596.03
|
|
$160.65
|
|||
|
|||||||||||||
(1)
|
Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Registrant’s common stock, par value $0.01 per share (“Common Stock”), that become issuable under the Registrant’s 2016 Equity Incentive Plan (the “2016 Plan”) or 2016 Employee Stock Purchase Plan (the “2016 ESPP”) by reason of any stock dividend, stock split, recapitalization or other similar transaction that results in an increase in the number of outstanding shares of Registrant’s Common Stock.
|
||||||||||||
(2)
|
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The offering price per share and the aggregate offering price are based upon the average of the high and low prices of the Common Stock as reported on The Nasdaq Capital Market on March 9, 2020.
|
||||||||||||
(3)
|
Represents an automatic increase to the number of shares of Common Stock available for issuance under the 2016 Plan effective January 1, 2020. Shares available for issuance under the 2016 Plan were previously registered on a registration statement on Form S-8 filed with the Securities and Exchange Commission (the “SEC”) on February 17, 2017 (Registration No. 333-216112).
|
||||||||||||
(4)
|
Represents an automatic increase to the number of shares of Common Stock available for issuance under the 2016 ESPP effective January 1, 2020. Shares available for issuance under the 2016 ESPP were previously registered on a registration statement on Form S-8 filed with the SEC on February 17, 2017 (Registration No. 333-216112).
|
|
MIRAGEN THERAPEUTICS, INC.
|
|
/s/ Jason A. Leverone
|
Jason A. Leverone
|
Chief Financial Officer, Treasurer and Secretary
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ William S. Marshall
|
|
President, Chief Executive Officer, and Director
|
|
March 13, 2020
|
William S. Marshall, Ph.D.
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Jason A. Leverone
|
|
Chief Financial Officer, Treasurer, and Secretary
|
|
March 13, 2020
|
Jason A. Leverone
|
|
(Principal Financial Officer; Principal Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Jeffrey S. Hatfield
|
|
Chairman of the Board
|
|
March 13, 2020
|
Jeffrey S. Hatfield
|
|
|
|
|
|
|
|
|
|
/s/ Christopher Bowden
|
|
Director
|
|
March 13, 2020
|
Christopher Bowden, M.D.
|
|
|
|
|
|
|
|
|
|
/s/ Thomas E. Hughes
|
|
Director
|
|
March 13, 2020
|
Thomas E. Hughes, Ph.D.
|
|
|
|
|
|
|
|
|
|
/s/ Kevin Koch
|
|
Director
|
|
March 13, 2020
|
Kevin Koch, Ph.D.
|
|
|
|
|
|
|
|
|
|
/s/ Arlene M. Morris
|
|
Director
|
|
March 13, 2020
|
Arlene M. Morris
|
|
|
|
|
|
|
|
|
|
/s/ Joseph L. Turner
|
|
Director
|
|
March 13, 2020
|
Joseph L. Turner
|
|
|
|
|
|
|
|
|
|
1 Year Miragen Therapeutics Chart |
1 Month Miragen Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions